Article Text
Therapeutics
Telmisartan did not prevent recurrent stroke or major cardiovascular events
Statistics from Altmetric.com
S Yusuf
Dr S Yusuf, McMaster University, Hamilton, Ontario, Canada; yusufs@mcmaster.ca
STUDY DESIGN
Design:
randomised placebo-controlled trial with 2 × 2 factorial design (Prevention Regimen for Effectively Avoiding Second Strokes [PRoFESS]). ClinicalTrials.gov NCT00153062.
Allocation concealment:
concealed.*
Blinding:
blinded {patients, clinicians, data collectors, outcome assessors, safety committee, and data analysts}†.*
STUDY QUESTION
Setting:
695 centres in 35 countries worldwide.
Patients:
20 332 …
Footnotes
Source of funding: Boehringer Ingelheim; Bayer Schering Pharm; GlaxoSmithKline.